Capricor Therapeutics, Inc. (CAPR) Stock Price & Analysis
Capricor Therapeutics, Inc. (CAPR) fell 0.57% to USD 26.01 as of June 10, 2026 at 01:54 UTC, according to Nexqual real-time market data.
CAPR last closed at USD 26.16; the session ranged USD 25.07–26.97 on volume of 962,886 shares. Market capitalization is $1.51B, with a 52-week range of USD 4.3–40.37 (NMS). Source: Nexqual, June 10, 2026 at 01:54 UTC.
Key Statistics (as of June 10, 2026 at 01:54 UTC)
| Price | USD 26.01 |
|---|---|
| Change | ▼ 0.57% (down) |
| Previous Close | USD 26.16 |
| Open | USD 26.52 |
| Day Range | USD 25.07 – 26.97 |
| 52-Week Range | USD 4.3 – 40.37 |
| Volume | 962,886 shares |
| Market Cap | $1.51B |
| Exchange | NMS |
Technical Analysis (CAPR)
Nexqual's technical model rates CAPR "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.08 (neutral) |
| vs SMA50 | Below (USD 31.19) |
| MACD | -1.3 (negative) |
Analyst Ratings (CAPR)
Wall Street analysts rate CAPR "Strong Buy" based on 9 analysts, with a mean price target of USD 54.11 (range USD 38–63), per Nexqual as of June 10, 2026 at 01:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 54.11 |
| High Target | USD 63 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (CAPR)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.59 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.62 vs est -0.55 ▼ miss |
| 2025-09-30 | USD -0.54 vs est -0.54 ▲ beat |
| 2025-06-30 | USD -0.57 vs est -0.48 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financials & Fundamentals (CAPR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -56.40% |
| Debt / Equity | 5.31 |
| Current Ratio | 8.42 |
| Total Cash | $278.61M |
| Total Debt | $14.78M |
| Free Cash Flow | $-70.47M |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financial Health Score (CAPR)
Nexqual rates Capricor Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:54 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $279M cash vs $15M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$93M |
| Efficiency | Critical — ROE -56%, ROA -31.2% |
Ownership (CAPR)
| Insider Ownership | +9.47% |
|---|---|
| Institutional Ownership | +59.72% |
| Shares Outstanding | 57.91M |
| Float | 48.55M |
| Short % of Float | +21.11% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Leadership (CAPR)
Capricor Therapeutics, Inc. is led by Linda Marbán (age 62), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 01:54 UTC.
| Co-Founder, President, CEO & Director | Linda Marbán (age 62) |
|---|---|
| Executive Chairman of the Board | Frank Isaac Litvack FACC (age 69) |
| CFO & Corporate Treasurer | Anthony J. Bergmann (age 39) |
| Chief Operating & Science Officer | Kristi A. H. Elliott |
| Senior Vice President of Quality Control, Research & Product Development | Minghao Sun |
Major Backers & Investors (CAPR)
Notable institutional backers of Capricor Therapeutics, Inc. include Suvretta Capital Management, LLC, Tang Capital Management, LLC, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 01:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 6.59% |
| Tang Capital Management, LLC | 5.87% |
| RA Capital Management, L.P. | 2.6% |
| Fidelity | 2.05% |
| Jones Hill Capital LP | 1.57% |
| Goldman Sachs | 1.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.29% |
| Vanguard Group | 7.25% |
| State Street | 6.01% |
| Geode Capital | 1.93% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
From Capricor Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Biologics License Application : In late 2024, we completed our submission of a BLA to the FDA seeking approval of Deramiocel for the treatment of Duchenne muscular dystrophy.
- Following a Type A meeting with the FDA in August 2025, we aligned with the Agency on a regulatory path forward to address the CRL, including the submission of additional clinical data from the Phase 3 HOPE-3 trial.
- Exosome Platform: Engineered Exosome-Based Vaccines : The StealthX™ vaccine is a proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
- In mid-2025, the FDA completed its Pre-License Inspection ("PLI") of this facility in connection with our Biologics License Application for Deramiocel.
Partnerships
- In addition, Capricor may terminate for any reason upon 60 days' written notice. ​ Cedars-Sinai Medical Center License Agreements License Agreement for CDCs On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the "Original CSMC License Agreement"), for certain intellectual property related to its CDC technology.
- License Agreement for Exosomes On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the "Exosomes License Agreement"), for certain intellectual property rights related to CDC-derived exosomes technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBRX | Moleculin Biotech, Inc. | USD 2.41 | ▲ 0.42% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| AYTU | Aytu BioPharma, Inc. | USD 2.3 | ▲ 2.22% |
| CFOR | OpGen, Inc. | USD 0.5 | ▲ 0% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:54 UTC. This page is informational and not investment advice.